SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:56S1 - FR0013154002 - Common Stock
204.7 EUR
-1.5 (-0.73%)
Overall 56S1 gets a fundamental rating of 4 out of 10. We evaluated 56S1 against 20 industry peers in the Life Sciences Tools & Services industry. While 56S1 is still in line with the averages on profitability rating, there are concerns on its financial health. 56S1 is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- 56S1 had positive earnings in the past year.
- 56S1 had a positive operating cash flow in the past year.
- Each year in the past 5 years 56S1 has been profitable.
- Each year in the past 5 years 56S1 had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 3.36%, 56S1 is doing worse than 65.00% of the companies in the same industry.
- The Return On Equity of 56S1 (6.55%) is worse than 60.00% of its industry peers.
- 56S1's Return On Invested Capital of 5.94% is in line compared to the rest of the industry. 56S1 outperforms 50.00% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for 56S1 is in line with the industry average of 9.00%.
- The 3 year average ROIC (10.41%) for 56S1 is well above the current ROIC(5.94%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.36% | ||
| ROE | 6.55% | ||
| ROIC | 5.94% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
- 56S1 has a Profit Margin of 8.98%. This is comparable to the rest of the industry: 56S1 outperforms 55.00% of its industry peers.
- In the last couple of years the Profit Margin of 56S1 has declined.
- With a Operating Margin value of 16.63%, 56S1 perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
- 56S1's Operating Margin has declined in the last couple of years.
- 56S1's Gross Margin of 45.64% is fine compared to the rest of the industry. 56S1 outperforms 65.00% of its industry peers.
- 56S1's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.98% | ||
| GM | 45.64% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
- 56S1 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- Compared to 1 year ago, 56S1 has more shares outstanding
- Compared to 5 years ago, 56S1 has more shares outstanding
- 56S1 has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 4.41 indicates that 56S1 is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 4.41, 56S1 is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
- The Debt to FCF ratio of 56S1 is 6.84, which is on the high side as it means it would take 56S1, 6.84 years of fcf income to pay off all of its debts.
- 56S1 has a Debt to FCF ratio of 6.84. This is in the lower half of the industry: 56S1 underperforms 60.00% of its industry peers.
- A Debt/Equity ratio of 0.50 indicates that 56S1 is not too dependend on debt financing.
- 56S1 has a Debt to Equity ratio (0.50) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.41 |
ROIC/WACC0.63
WACC9.36%
2.3 Liquidity
- A Current Ratio of 1.05 indicates that 56S1 should not have too much problems paying its short term obligations.
- 56S1 has a worse Current ratio (1.05) than 70.00% of its industry peers.
- 56S1 has a Quick Ratio of 1.05. This is a bad value and indicates that 56S1 is not financially healthy enough and could expect problems in meeting its short term obligations.
- 56S1 has a worse Quick ratio (0.50) than 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 35.11% over the past year.
- 56S1 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.19% yearly.
- 56S1 shows a small growth in Revenue. In the last year, the Revenue has grown by 7.72%.
- Measured over the past years, 56S1 shows a quite strong growth in Revenue. The Revenue has been growing by 14.05% on average per year.
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
3.2 Future
- 56S1 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.17% yearly.
- The Revenue is expected to grow by 9.86% on average over the next years. This is quite good.
EPS Next Y29.39%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
EPS Next 5Y21.17%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y9.86%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 47.49, which means the current valuation is very expensive for 56S1.
- Based on the Price/Earnings ratio, 56S1 is valued more expensive than 80.00% of the companies in the same industry.
- 56S1 is valuated expensively when we compare the Price/Earnings ratio to 27.21, which is the current average of the S&P500 Index.
- 56S1 is valuated quite expensively with a Price/Forward Earnings ratio of 38.12.
- 56S1's Price/Forward Earnings ratio is rather expensive when compared to the industry. 56S1 is more expensive than 80.00% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.26, 56S1 is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.49 | ||
| Fwd PE | 38.12 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, 56S1 is valued expensively inside the industry as 85.00% of the companies are valued cheaper.
- 56S1's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 65.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 53.19 | ||
| EV/EBITDA | 27.46 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- 56S1's earnings are expected to grow with 23.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.62
PEG (5Y)11.32
EPS Next 2Y23.86%
EPS Next 3Y23.06%
5. Dividend
5.1 Amount
- 56S1 has a yearly dividend return of 0.32%, which is pretty low.
- 56S1's Dividend Yield is slightly below the industry average, which is at 0.54.
- With a Dividend Yield of 0.32, 56S1 pays less dividend than the S&P500 average, which is at 1.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.32% |
5.2 History
- The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
- 25.37% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
- The dividend of 56S1 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP25.37%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.
Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
How profitable is SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for 56S1 stock?
The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 47.49 and the Price/Book (PB) ratio is 4.94.
What is the earnings growth outlook for SARTORIUS STEDIM BIOTECH?
The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 29.39% in the next year.